Quick Answer
Cabaletta Bio, Inc. reported Cash And Cash Equivalents At Carrying Value of $82.98 million for the year ending 2025.
- Cabaletta Bio, Inc. showed a decrease of -49.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Cabaletta Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $71.04 million | Q1 2020: $131.00 million | Q2 2020: $112.10 million | Q3 2020: $108.68 million | Q1 2021: $97.28 million | Q2 2021: $99.50 million | Q3 2021: $118.26 million | Q1 2022: $59.55 million | Q2 2022: $47.17 million | Q3 2022: $61.16 million | Q1 2023: $93.85 million | Q2 2023: $128.07 million | Q3 2023: $115.50 million | Q1 2024: $175.29 million | Q2 2024: $178.61 million | Q3 2024: $170.61 million | Q1 2025: $131.83 million | Q2 2025: $145.61 million | Q3 2025: $60.21 million.
- Over the full 8 years of available data (2018 to 2025), Cabaletta Bio, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 151.3%.
- Historical annual values: Fiscal year 2025: $82.98 million | Fiscal year 2024: $163.96 million | Fiscal year 2023: $193.24 million | Fiscal year 2022: $81.61 million | Fiscal year 2021: $122.22 million | Fiscal year 2020: $101.43 million | Fiscal year 2019: $136.20 million | Fiscal year 2018: $33.02 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: